The antimicrobial activity of flumequine (R-802) was characterized by in vitro and in vivo procedures. Assay of the minimal inhibitory concentrations for 321 recent clinical isolates revealed that 88% of the gram-negative bacteria were inhibited by an R-802 concentration of 6.2 ,ug/ml or less. Cross-resistance in laboratory-derived mutants ofProteus vulgaris was essentially complete for R-802, nalidixic acid, and oxolinic acid, although quantitative differences were evident. R-802 was more effective than either of these quinolone antibacterials in preventing the development of experimental murine pyelonephritis (P. vulgaris). R-802 and trimethoprim/sulfamethoxazole (1:5) were equally effective in resolving a P. mirabilis-induced prostatitis of rats.
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Flumequine (R-802) is a synthetic antibacterial, selected from a series of tricyclic quinolines prepared in Riker Laboratories. The compound is 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H (U) quinolizine-2-carboxylic acid (Fig. 1 ). This report describes the bioevaluation of R-802 and its comparison with several antimicrobials in clinical use.
(This work was reported in part at the Annual Meeting of the Federation of American Societies for Experimental Biology, 1974, Atlantic City, N.J.) MATERIALS AND METHODS Bacteria. Laboratory stock cultures were used. Susceptibility testing of clinical isolates was accomplished with cultures from urine specimens taken at the St. Paul Veterans Administration Hospital, St. Paul, Minn. These isolates were identified using conventional microbiological methods (1) . Wound isolates of Staphylococcus aureus were obtained from the St. Louis Park Clinic, Minneapolis.
Antimicrobials. Flumequine (R-802) was synthesized in Riker Research Laboratories. Stock solutions of R-802 (1%) for in vitro use were prepared with 0.1 N sodium hydroxide. Nalidixic acid and oxolinic acid were provided by Winthrop Laboratories and Warner-Lambert Research Institute, respectively. Bactrim (sulfamethoxazole and trimethoprim, 5:1), Erythrocin (erythromycin stearate), and Terramycin (oxytetracyline-hydrochloride) were obtained in commercial form.
Susceptibility. The antimicrobial spectrum of R-802 was surveyed on tryptone soy agar (TSA) plates with a log,0 dilution series. Microliter aliquots of stock solution were mixed with molten TSA in individual screw-cap vials and dispensed into petri dishes. These preparations were allowed to harden and were surface inoculated with stock culture suspensions. The conditions of incubation were overnight at 37 C in a humidified atmosphere enriched with 10% carbon dioxide. Growth inhibition of those strains that appeared to be most susceptible to R-802 was further examined by a log2 dilution tube technique in nutrient broth (5) . Nalidixic acid and oxolinic acid were included in this titration as reference quinolone antibacterials. Bacillus subtilis was deleted in this comparison because of pellicle formation in static broth culture; Proteus vulgaris, which was not tested on TSA because of the "swarming" phenomenon, was included here. The minimal inhibitory concentrations (MICs) of R-802 for clinical isolates of urinary tract infection were similarly determined; the influence ofculture medium pH was examined in selected strains at 0.2-unit intervals over the range 6.0 to 8.0.
Cross-resistance of mutant clones selected by growth on oxolinic acid, nalidixic acid, and R-802 was assessed by the replica plating technique (6) . Approximately 109 cells were spread over the surface of drug plates containing TSA plus 0.15% bile salts to inhibit swarming ofP. vulgaris 210. The levels of drug permitting development of approximately 10 colonies/plate were as follows: R-802 and oxolinic acid, 10 ,ig/ml; nalidixic acid, 50 ,ug/ml. No colonies were observed on plates containing 25 ,ug of R-802 or oxolinic acid per ml. An imprint of the colonies developing on each original plate was transferred to sterile velveteen templates. These in turn were used to reproduce the patterns on several test plates containing the individual drugs. All plates were scored after 2 days of incubation at 37 C.
Efficacy. Preclinical evaluation of R-802 for treatment of urinary tract infection used a rat model, which mimics the development of bacterial pyelonephritis in humans (8 
RESULTS
In vitro. The susceptibility to R-802 of selected strains of microorganisms is presented in Table 1 . The concentrations of R-802 inhibiting growth of bacteria ranged from 1 to 100 jig/ml, whereas no antifungal activity was evident at 100 ,ug of R-802 per ml. Antibacterial activity was unchanged by the addition of 10% (vol/vol) horse serum to the TSA growth medium.
The MICs of quinolone antibacterials presented in Table 2 suggested that a study of the response of recent clinical isolates from urinary tract infection to R-802 should be pursued. No "skip-tube" end points indicating rapid selection of resistant progeny were evident in this experiment.
Assay of the R-802 MICs for 321 recent clinical isolates ( VA-1, and P. mirabilis VA-3 were invariant in the pH range 6.0 to 8.0; the MIC for S. aureus 148 increased 10-fold to a maximum of 25.0 ug/ ml at pH 8.0.
Cross-resistance in laboratory-derived mutants ofP. vulgaris was essentially complete for R-802, nalidixic acid, and oxolinic acid (Table  4) . Although discrete colonies were evident on nalidixic acid selection plates containing 10 ug of drug per ml, a background lawn of additional mutants was confirmed on replica plates. Multistep mutants selected by serial transfers in increasing concentrations of each drug confirmed these observations: cross-resistance was demonstrated for P. vulgaris clones capable of growing on TSA containing 100 ,ug of R-802, 100 ,ug of oxolinic acid, or 500 Mg of nalidixic acid per ml.
In vivo. the R-802 dose response obtained in an ascending rat urinary tract infection model is presented in The comparative efficacy of R-802 and two urinary tract antimicrobials is presented in Table 6 . The performance of nalidixic acid was comparable to that of oxolinic acid, whereas R-802 was clearly more effective in preventing the development ofpyelonephritis as defined in this model. Bladder isolates from the two R-802 treatment failures were indistinguishable from the infecting culture in terms of antimicrobial susceptibility.
The absence of infection relapse in a shortterm follow-up experiment is evident in Table  7 . Bladder isolates from the four rats treated The therapeutic response to R-802 and three reference antimicrobials in a P. mirabilis-induced prostatitis is presented in Table 8 . In three experiments, the incidence of positive prostate cultures from infection control groups of 10 animals each ranged from 0.72 to 0.86; positive cultures from both kidneys of each animal closely paralleled the incidence of prostate infection. The incidence of bladder infection was slightly higher, as indicated. R-802 was essentially ineffective in this model at a dose of 
